Caprion Pharmaceuticals completed Phase I studies for Shigamabs, its product for the treatment of Shigatoxin-producing E. coli infections (STEC), including the O157:H7 strain involved in the current U.S. outbreak. The severe clinical symptoms such as hemorrhagic colitis, thrombocytopenia, hemolytic anemia and hemolytic uremic syndrome in as many as 60% of all infected patients, are potentially lethal in the most severe cases. Serious complications are most frequent in young children and the elde...